Rehabilicare Issued U.S. Patent for Ortho Dx High-Volt Pulsed Current and Neuromuscular Stimulation Device.

Business/Medical & Health Editors

NEW BRIGHTON, Minn.--(BW HealthWire)--June 12, 2000

Rehabilicare Inc. (NASDAQ NM: REHB) announced receipt from the U.S. Patent and Trademark Office of patent number 6,064,911, entitled "Device Using Both HVPC and NMS Electrotherapy." The technology addressed by this patent is used in the Company's Ortho Dx(TM) portable, dual-purpose neuromuscular stimulator device. The Ortho Dx requires a prescription from a physician, and is available at physical therapy clinics across the U.S.

"This easy-to-use electrotherapy device is an important part of the Rehabilicare product line, and represents our commitment to leading-edge technology for pain management and rehabilitation. During the past year, we recorded a 23% increase in sales for this product, compared with single-digit growth in the U.S. electrotherapy market," said David Kaysen, president and chief executive officer. "Our Ortho Dx patients tell us that they are experiencing reduced pain and swelling, and increased range of motion, with an easy to use product. Our Physical Therapy clinics like the product's versatility."

Designed to help patients achieve their therapy goals faster and more comfortably, the Ortho Dx utilizes two proven modalities - either separately or together - to aid in reducing pain and swelling while enhancing muscle contractions. Ortho Dx is a cost-effective alternative to aid in the treatment of knee and shoulder joint injuries, and to assist the healing process following arthroscopic and anterior cruciate ligament (ACL) surgeries, among other disorders.

The Ortho Dx is used by patients in their homes, and features color-coded lead wires and electrodes for easy set up and use. The device combines two large clinical modalities into one small package that is portable and easy to wear. In addition, the dual currents allow for faster recovery time and may be preprogrammed to aid in comfort. The Ortho Dx is most beneficial when applied one to two weeks before surgery, as well as within the first two weeks after surgery or injury.

Rehabilicare is a leading designer, manufacturer and provider of electromedical pain management and rehabilitation products and services used for clinical, sports medicine, home health care and occupational medicine applications.

Statements in this press release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. All such statements are subject to risks and uncertainties, and are discussed more fully in the Company's annual report on Form 10-KSB and other filings with the Securities and Exchange Commission.